Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea.Positive study results are a ...
AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant improvement in ...
Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...
Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by ...
The GNPS Drug Library may be more broadly applicable for drug screening across diverse research disciplines, such as food and environmental monitoring.
Despite granting the FDA enhanced authority to mandate postmarketing studies, revise safety labels, and enforce active surveillance, the FDAAA was not associated with statistically significant ...
Preliminary studies indicate that derivatives of verticillin A can kill certain types of glioma cells. MIT chemists have, for ...
ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...
Xelafaslatide is an investigational, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal ...
Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...
Presented in an oral session at the 67th American Society of Hematology Annual Meeting & Exposition ...
The poster presentation, titled “COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Basic Characteristics” (Reference # CTL-21), highlighted the following: Overview of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback